UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

~~Current~~CURRENT ~~Report Pursuant~~REPORT

Pursuant to Section 13 orOR 15(d) of ~~the~~

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2007

December 8, 2006

SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-26694	93-0945003
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)


585 West 500 South Bountiful, Utah		84010
(Address of principal executive offices)		( (Zip Code)


Registrant’s telephone number, including area code (801) 298-3360

SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

0-26694	93-0945003
(Commission file number)	(IRS employer identification no.)
585 West 500 South, Bountiful, Utah	84010
(Address of principal executive offices)	(Zip code)

(801) 298-3360

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Soliciting~~Item ~~material~~2.02. ~~pursuant~~Results toof ~~Rule 14a-12~~Operations ~~under~~and ~~the~~Financial ~~Exchange Act (17 CFR 240.14a-12)~~Condition

~~Pre-commencement~~On ~~communications~~May ~~pursuant~~9, to2007, ~~Rule 14d-2~~Specialized Health Products International, Inc. (bthe “Company”) ~~under~~ issued a press release announcing financial results for its first quarter ended March 31, 2007. A copy of the ~~Exchange~~press ~~Act~~release ~~(17~~is ~~CFR~~attached ~~240~~hereto as Exhibit 99.~~14d-2(b))~~1 to this report, and incorporated herein by reference.

~~Pre-commencement~~The ~~communications~~Company ~~pursuant~~will conduct a conference call to ~~Rule 13e-~~discuss its financial results for its first quarter ended March 31, 2007 on Wednesday, May 9, 2007, at 4:30 p.m. Eastern Time. Investors can participate in the conference call live by dialing (c800) 230-1085 in the U.S. and ~~under~~(612) 234-9960 internationally. In addition, the ~~Exchange~~call ~~Act~~will ~~(17~~be ~~CFR~~webcast ~~240~~live and available for playback within one hour of completion of the call through a link on the Company’s website at www.~~13e~~shpi.com. A replay of the call will also be available for one week after the event by dialing (800) 475-46701 in the U.S. and (c320)) 365-3844 internationally and entering access code 871947.

Item 89.01. ~~Other~~Financial ~~Events~~Statements and Exhibits.

~~A new trial has been set to begin on November 27, 2007, in the pending patent infringement lawsuit filed by Becton Dickinson~~ (~~“BD”~~d) ~~against~~Exhibits ~~Tyco~~Number ~~Healthcare related to the Monoject Magellan™ safety products manufactured and marketed by Tyco Healthcare.~~Description

In99.1 ~~December~~Press ~~2002~~Release, BDdated ~~filed~~May a9, ~~lawsuit~~2007, ~~against~~announcing ~~Tyco Healthcare in~~ the ~~United States Court of the District of Delaware, asserting that Tyco Healthcare~~Company’s ~~Monoject~~financial ~~Magellan™~~results ~~safety~~for ~~products~~its ~~infringe~~first ~~upon~~quarter ~~BD’s~~ended ~~U.S.~~March ~~Patent No. 5~~31,~~348,544~~ ~~(‘544 Patent), titled “Single-Handedly Actuable Safety Shield for Needles~~2007.~~” Tyco Healthcare developed the Monoject Magellan™ safety products in association with us. We are not a party to the patent infringement lawsuit.~~

On October 26, 2004, a jury found in favor of BD that Tyco Healthcare’s Monoject Magellan™ safety products willfully infringed the ‘544 Patent. On November 1, 2004, the court entered the judgment in favor of BD. Tyco Healthcare challenged the jury finding in post-trial motions. On March 31, 2006, the court granted Tyco Healthcare’s motion for a new trial on the issue of infringement with respect to the ‘544 Patent. 2

Under our arrangements with Tyco Healthcare, Tyco Healthcare has the right to withhold up to fifty percent (50%) of royalties due as an offset against litigation expenses related to charges of infringement by a third party for the manufacture, use or sale of licensed product. This right continues through the period of the new trial and thereafter while this litigation is pending. If, as a result of judgment in the litigation or settlement with BD, Tyco Healthcare is required to pay royalty and/or other monies to BD, Tyco Healthcare may thereafter deduct from the amount of royalties due us on unit sales of products alleged to infringe, an amount which is the lesser of all royalties and/or other monies paid by Tyco Healthcare to BD, or fifty percent (50%) of all royalty payments otherwise payable to us.SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SPECIALIZED HEALTH PRODUCTS
	INTERNATIONAL, INC.


Date: May 9, 2007	By:	/s/ JEFFREY M. SOINSKI
		Jeffrey M. Soinski
		President, Chief Executive Officer and Director

~~Date: December 13, 2006 SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC. By /s/ Jeffrey M. Soinski Jeffrey M. Soinski President, Chief Executive Officer, Director~~3

EXHIBIT INDEX

Exhibit No.	Description of Document
99.1	Press Release, dated May 9, 2007, announcing the Company’s financial results for its first quarter ended March 31, 2007

Filing Compare · SPECIALIZED HEALTH PRODUCTS INTERNATIONAL INC